$ICR-PA

Determination of September 30, 2026 NAV per Share InPoint Commercial Real Estate Income, Inc. calculates net asset value per share in accordance with the…

InPoint Commercial Real Estate Income, Inc. (ICR-PA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Determination of September 30, 2026 NAV per Share InPoint Commercial Real Estate Income, Inc. (the “Company,” “we,” “our”) calculates net asset value (“NAV”) per share in accordance with the valuation guidelines that have been approved by its Board of Dire

Original reporting
Published Oct 15, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ICR-PA
Neutral
medium confidence
Mentioned
$ICR-PA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ICR-PANeutralLow
01

Why it matters

The 8-K provides the September 30, 2026 NAV per share (and class-level NAV per share) plus major NAV components such as commercial mortgage loans, real estate owned, and liabilities including repurchase agreements and mortgage loan payable.

02

Market read

This is a valuation datapoint for ICR-PA, useful for NAV-based positioning but not a standalone catalyst.

03

What to watch

Traders may care more about the trend in NAV and underlying loan performance than the single-month snapshot; without prior-month comparisons, the signal is weaker.

Relevance 4/10Novelty 4/10Timing: as-of September 30, 2026 NAV per share disclosed on Oct 15, 2026

Background

The company updates NAV per share as of the last calendar day of each month using valuation guidelines approved by its Board, with the Advisor responsible for the calculation.

Company-level read

Ticker impact

$ICR-PANeutralMedium confidence
Context

ICR-PA filed an 8-K disclosing its September 30, 2026 NAV per share and the component breakdown used for monthly updates.

Expected impact

Likely limited near-term impact, with traders focusing on whether NAV trends are improving or deteriorating versus prior months.

Evidence & confidence

This is a routine monthly NAV calculation disclosure under approved valuation guidelines, not a surprise earnings, guidance, or capital-structure event.

Market effects

Adds data for commercial mortgage REIT valuation models, but does not change sector policy or credit conditions directly.

No direct regional market linkage beyond the company’s underlying commercial mortgage exposure.

No direct global macro or cross-border transaction impact described.

Counterpoint

NAV per share updates may be largely mechanical and already anticipated by market participants, so price reaction may be muted.

Key entities

  • InPoint Commercial Real Estate Income, Inc.

    Issuer of the 8-K that discloses September 30, 2026 NAV per share and NAV component breakdown.

  • Inland InPoint Advisor, LLC

    Advisor responsible for determining NAV under the company’s valuation guidelines.

  • Inland Securities Corporation

    Dealer Manager referenced for stockholder servicing fee accruals related to certain share classes.

Related articles

$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

$ABTMed

Abbott Plans to Spin Off Its Nutrition Business

Abbott plans to spin off its nutrition business, which generates $8.5bn in annual revenue, into an independent publicly traded company by the end of 2027. The move aims to allow both entities to focus on their respective markets. Abbott's remaining business will have $42bn in revenue and focus on medical devices, diagnostics, and pharmaceuticals. The transaction is subject to regulatory approvals and will not impact Abbott's 2026 and 2027 guidance.

$ABTMed

Abbott Laboratories (ABT) Plans Nutrition Spin-Off Amid Dividend

Abbott Laboratories (ABT) plans to spin off its Nutrition division, including brands like Similac, by the end of 2027. The move aims to unlock shareholder value, with the new entity to be led by Daniel Salvadori. Abbott's shares trade at a 24.5% discount to its GF Value of $135.69, offering a 2.59% dividend yield with a high payout ratio of 80%. The company reported better-than-expected Q3 2026 results but saw a slight share price dip post-announcement.